Literature DB >> 8164450

The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure.

P Ureña1, M Kubrusly, M Mannstadt, M Hruby, M M Trinh, C Silve, B Lacour, A B Abou-Samra, G V Segre, T Drüeke.   

Abstract

Hypocalcemia, hyperphosphatemia, and resistance to the action of PTH are well characterized features in the setting of advanced chronic renal failure (CRF). Although the underlying mechanisms are ill-understood, clinical and experimental evidence points to both PTH receptor down-regulation and post-receptor abnormalities in their pathogenesis. In the present study we have examined the effect of advanced CRF in rats on the renal expression of PTH/PTHrP receptor (PTH-R). CRF was created by a standard two-step operation (5/6 nephrectomy). Four weeks thereafter, 19 uremic rats were compared with 23 sham-operated rats. Uremic rats had higher mean (+/- SD) plasma creatinine levels than control rats, 164 +/- 107 microM versus 43 +/- 5 microM, respectively. They also had higher plasma phosphorus and iPTH levels, 4.70 +/- 1.71 mM versus 2.59 +/- 0.37 mM and 561 +/- 336 versus 27 +/- 18 pg/ml, respectively. Mean plasma total calcium and blood ionized calcium were significantly lower in uremic than in control rats, 2.13 +/- 0.06 mM versus 2.61 +/- 0.10 mM and 1.07 +/- 0.11 versus 1.31 +/- 0.06 mM, respectively. Mean plasma calcitriol concentration was also significantly lower in uremic than in control rats, 39.8 +/- 14.6 and 80.4 +/- 15.2 pg/ml, respectively. Nine out of the 19 rats were examined for renal PTH-R gene expression.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164450     DOI: 10.1038/ki.1994.79

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

2.  Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.

Authors:  Mengjing Wang; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jing Chen; Chuanming Hao; Takayuki Hamano; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-09       Impact factor: 8.237

3.  Expression of bone type 1 PTH receptor in rats with chronic renal failure.

Authors:  Michio Kuwahara; Seiji Inoshita; Yukiko Nakano; Yoshio Terada; Yoshiro Takano; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

Review 4.  Uremic Toxicity and Bone in CKD.

Authors:  Suguru Yamamoto; Masafumi Fukagawa
Journal:  J Nephrol       Date:  2017-06-01       Impact factor: 3.902

5.  Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting.

Authors:  Verónica Alonso; Clara E Magyar; Bin Wang; Alessandro Bisello; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

6.  NHERF1 regulates parathyroid hormone receptor desensitization: interference with beta-arrestin binding.

Authors:  Bin Wang; Yanmei Yang; Abdul B Abou-Samra; Peter A Friedman
Journal:  Mol Pharmacol       Date:  2009-02-02       Impact factor: 4.436

7.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

Review 8.  Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia.

Authors:  T B Drüeke
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

9.  Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone.

Authors:  M Klin; M Smogorzewski; Z Ni; G Zhang; S G Massry
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

10.  Mutation of phenylalanine-34 of parathyroid hormone disrupts NHERF1 regulation of PTH type I receptor signaling.

Authors:  David Wheeler; W Bruce Sneddon
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.